



Piston Bio

New Medicine for Cancer and Autoimmune Disease

October 2026

Walter Hong, MD
Chief Executive Officer
walterhong@pistonbio.com

Pipeline



Program	Mechanism	Target Indication	Rights Status	IP	Stage
Mosperafenib	BRAF V600E inhibitor	2L+ BRAF V600E CRC	Non-binding terms agreed with Roche	Roche IP	Phase Ib completed
PST-102	Extended half-life TLR7/8 agonist	2L+ NSCLC	100% owned	Composition of matter	Pre-IND / FDA feedback received
PST-101	Extended half-life A2A antagonist	Cancer-related apathy	100% owned	Composition of matter	FDA-aligned Phase 2

Current \$18M financing is dedicated exclusively to mosperafenib development.

Mosperafenib

Clinical-stage, oral BRAF inhibitor | Proposed Roche licensing opportunity



MECHANISM

Paradox-breaking BRAF inhibition

LEAD INDICATION

Previously treated BRAF V600E metastatic colorectal cancer

ADDITIONAL OPPORTUNITY

BRAF V600E melanoma

DEVELOPMENT PLAN

Proposed Phase 2 clinical evaluation

Transaction status: Agreed non-binding terms.


PST-102: Extended Half-Life TLR7/8 Agonist

Designed for sustained TLR7/8 engagement with Q3W IV dosing

1

Resiquimod

Clinical precedent: BDB001/EIK1001



2

PST-102

Proprietary molecular modification

**DESIGNED TO
EXTEND EXPOSURE**


while preserving
TLR7/8 pharmacologic activity



3

Extended Exposure

Designed for sustained
target engagement



In monotherapy, given weekly IV:

- 18% (2/11) durable irPR in NSCLC and RCC; 64% (7/11) DCR
- Clinical safety, PK, and PD

- PK/PD to be confirmed

- Potential for sustained innate and adaptive immune priming

PST-102: FDA Pre-IND Regulatory Milestone Achieved



October 5, 2026 written responses define a clear path to IND

1

ICH S9 Framework

Agreed 2L+ NSCLC qualifies for accelerated oncology development.

2

IND-Enabling Studies

FDA defined a focused comparative program covering PK and PD; toxicology reduced to one study in rodents.

3

Clinical Studies

Endorsed ORR primary endpoint via BICR and Phase 2 statistical design.

4

Regulatory Pathway and CMC

Confirmed 505(b)(1) regulatory pathway and endorsed CMC quality/specifications.

PST-102: Billion-Dollar Opportunity in 2L+ NSCLC

Unmet need: 2.6% five-year overall survival with docetaxel

TAM \$20-30B+

Global NSCLC therapeutics market

SAM \$3-6B

~150K-220K 2L+ NSCLC patients annually (US + EU)

Post-PD-1 where standard; inclusive of global PD-1-naïve patients

SOM / Peak sales: \$1B+

20–30% share of 2L+ NSCLC market

Add-on to docetaxel

PST-101: FDA Alignment Establishes Phase 2 Path

- Type B Pre-IND meeting completed with FDA
- FDA alignment established key elements of the proposed Phase 2 clinical development strategy for the parent A2A receptor antagonist program in cancer-related apathy.
 - Randomized, placebo-controlled study
 - NSCLC
 - Primary endpoint: AES-C
- PST-101 has since evolved into a proprietary next-generation A2A receptor antagonist protected by composition-of-matter intellectual property.
- The FDA-aligned clinical development strategy provides a strong regulatory foundation for advancing next-generation PST-101

World-Class Leadership & Advisors



Walter Hong, MD

Founder and CEO, Piston Bio

30 Years of Clinical Development Experience



Antoni Ribas, MD, PhD

UCLA – Tumor Immunology



Adil Daud, MD

UCSF – Melanoma Clinical Research



Matthew Zibelman, MD

Fox Chase Cancer Center – Genitourinary Research

Why Piston Bio

- Mosperafenib: Non-binding licensing terms agreed with Roche for a clinical-stage BRAF V600E inhibitor
- PST-102: FDA Pre-IND written responses received October 5, 2026
- PST-101: FDA-aligned Phase 2 development strategy for cancer-related apathy
- Proprietary IP: Composition-of-matter patent applications for PST-101 and PST-102
- Capital-efficient strategy: Combining internally developed medicines with clinical-stage in-licensing opportunities